Japan Ophthalmic Devices & Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Japan Eye Care Market and the market is segmented by Product (Devices (Surgical Devices (Intraocular Lenses, Ophthalmic Lasers, and Other Surgical Devices), and Diagnostic Devices), and Drugs (Glaucoma Drugs, Retinal Disorder Drugs, Dry Eye Drugs, Allergic Conjunctivitis and Inflammation Drugs, and Other Drugs), and Disease (Glaucoma, Cataract, Age-Related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Other Diseases). The market provides the value (in USD million) for the above-mentioned segments.

Japan Ophthalmic Device & Drug Market Size

Japan Ophthalmic Devices & Drugs Market
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 2.00 %
Market Concentration Medium

Major Players

Japan Ophthalmic Devices & Drugs Market

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Japan Ophthalmic Device & Drug Market Analysis

Japan Ophthalmic Devices & Drugs Market is poised to grow at a CAGR of 2% during the forecast period (2022-2027).

The COVID-19 pandemic led to disruption in not only the research and development activities of other therapies and drugs for medical conditions other than COVID-19 but also impacted the treatment procedures and supply chain of the pharmaceuticals and medical devices around the world which also impacted the studied market. For instance, the impact of COVID-19 has caused very serious and irreversible consequences in people with glaucoma, who have suffered a very rapid evolution of the disease and have not been able to carry out follow-up by the specialist, which, in some cases, has resulted in a loss of the visual field, according to a health article published in March 2021, titled "The Covid-19 pandemic accelerates the worsening of glaucoma cases" stated that the COVID-19 pandemic has increased concern among glaucoma patients, and the overall result showed that the patients were more concerned for their glaucoma care as a result of the closure of the care centers or postponement of their appointments, which not only affected the treatment procedures but also had an impact on the diagnostics services. This is according to the research study published in February 2021, titled "The impacts of COVID-19 on glaucoma patient outcomes as assessed by POEM." Therefore, the overall impact of COVID-19 on Japan ophthalmic devices & drugs market was negative primarily due to the decline in the diagnostics and treatment procedures of the diseases associated with the eye but with the ongoing vaccination programs and launch of new drugs against the COVID-19, the studied market is expected to beam back to its full potential in due time.

Certain factors that are driving the growth of the market include demographic shift, the impact of the prevalence of eye disease, technological advancements in the field of ophthalmology, and the rising geriatric population. The data from the Ministry of Internal Affairs and Communications 2021, has stated that a record high of 36.4 million persons in Japan was predicted to be 65 or older as of September 2021, which was an increase of around 220,000 compared to that of the year 2020. Similarly, increasing cases of glaucoma is another factor in market growth. According to a November 2020 article in the Clinical Epidemiology Journal titled "Detection of Glaucoma and Other Vision-Threatening Ocular Diseases in the Population Recruited at Specific Health Checkups in Japan," 12.4% of the population under study had been given a glaucoma diagnosis, and 2.4% had preperimetric glaucoma. Furthermore, macular degeneration (1.2%), diabetic retinopathy (1.0%), chorioretinal atrophy (0.5%), macular epiretinal membrane (2.9%), branch retinal vein occlusion (0.7%), and other retinal illnesses (2.0%) were all prevalent. The prevalence of these disorders is promoting market growth in the country, Additionally, the initiatives by key market players are another factor in market growth. For instance, in June 2021, the market leader in ophthalmic lens technology, HOYA Vision Care, unveiled its eagerly awaited Visionary Alliance loyalty programme. This programme is intended to meet and exceed the professional needs of independent ECPs by providing them with a global knowledge base, business tools, advice, and support to enable them to run their businesses independently. Similarly, in March 2021, Johnson & Johnson Vision received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first and only vision correction contact lens that relieves allergic eye itch named as ACUVUE Theravision with Ketotifen. Thums the abovementiond factors are expected to increase the market growth.

However, the higher cost of ophthalmic devices and treatment is expected to hinder market growth.

Japan Ophthalmic Device & Drug Market Trends

This section covers the major market trends shaping the Japan Ophthalmic Devices & Drugs Market according to our research experts:

Glaucoma Segment is Expected to Show Better Growth in the Forecast Years

Since 1950, the proportion of elderly individuals in Japan has increased. According to the National Institute of Population and Social Security Research 2021 report, when the people born in the early 1970s would reach the age of 65 or older in 2040, the percentage might reach as high as 35.3%. The growing older population indicates the future need for ophthalmic devices and drugs, which is likely to contribute to the growth of the market studied. According to a November 2020 article in the Clinical Epidemiology Journal titled "Detection of Glaucoma and Other Vision-Threatening Ocular Diseases in the Population Recruited at Specific Health Checkups in Japan," 12.4% of the population under study had been given a glaucoma diagnosis, and 2.4% had preperimetric glaucoma. Furthermore, macular degeneration (1.2%), diabetic retinopathy (1.0%), chorioretinal atrophy (0.5%), macular epiretinal membrane (2.9%), branch retinal vein occlusion (0.7%), and other retinal illnesses (2.0%) were all prevalent. Thus,
the market is expected to grow due to the burden of diseases.

Collaboration between industry participants and nonprofit groups to increase public awareness is helping the market expand. A project launched by the Japan Glaucoma Society to raise public awareness of glaucoma is Light-up in Green, which Santen Pharmaceutical Co., Ltd. supports in March 2020. Such campaigns increase public awareness of the condition, which increases demand for the medications employed in the treatment and propels market expansion. Collaboration between market participants and the introduction of new items both help the market grow. Aerie Pharmaceuticals, Inc. and Santen Pharmaceutical Co., Ltd., for example, signed into an exclusive research and commercialization deal for Rhopressa and Rocklatan in Japan in October 2020. This arrangement also included rights for several other Asian nations. These agreements are accelerating the market's expansion. Thus, the above-mentioned factors are expected to increase market growth.

image

Japan Ophthalmic Device & Drug Industry Overview

The Japan Ophthalmic Devices & Drugs Market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Essilor International SA, Johnson & Johnson, Nidek Co. Ltd, Topcon Corporation, and Ziemer Group AG among others.

Japan Ophthalmic Device & Drug Market Leaders

  1. Nidek Co. Ltd

  2. Alcon Inc.

  3. Bausch Health Companies Inc

  4. Carl Zeiss Meditec AG

  5. Topcon Corporation

*Disclaimer: Major Players sorted in no particular order

Picture7.png
Need More Details on Market Players and Competitors?
Download PDF

Japan Ophthalmic Device & Drug Market News

  • In July 2022, NIDEK TECHNOLOGIES S.R.L., a subsidiary of NIDEK CO., LTD. acquired 90% of the shares of NIDEK MEDICAL S.R.L., a sales and service company of ophthalmic devices.
  • In January 2022, Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. initiated a prospective study in Japan using our Patient Based Ophthalmology Suite (PBOS), an in-home optical coherence tomography device.

Japan Ophthalmic Device & Drug Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Demographic Shift and Impact of Prevalence of Eye Disease

      2. 4.2.2 Technological Advancements in the Field of Ophthalmology

    3. 4.3 Market Restraints

      1. 4.3.1 Higher Cost of the Ophthalmic Devices and Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Product

      1. 5.1.1 Devices

        1. 5.1.1.1 Surgical Devices

          1. 5.1.1.1.1 Intraocular Lenses

          2. 5.1.1.1.2 Ophthalmic Lasers

          3. 5.1.1.1.3 Other Surgical Devices

        2. 5.1.1.2 Diagnostic Devices

      2. 5.1.2 Drugs

        1. 5.1.2.1 Glaucoma Drugs

        2. 5.1.2.2 Retinal Disorder Drugs

        3. 5.1.2.3 Dry Eye Drugs

        4. 5.1.2.4 Allergic Conjunctivitis and Inflammation Drugs

        5. 5.1.2.5 Other Drugs

    2. 5.2 By Disease

      1. 5.2.1 Glaucoma

      2. 5.2.2 Cataract

      3. 5.2.3 Age-Related Macular Degeneration

      4. 5.2.4 Inflammatory Diseases

      5. 5.2.5 Refractive Disorders

      6. 5.2.6 Other Diseases

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alcon Inc.

      2. 6.1.2 Bausch Health Companies Inc.

      3. 6.1.3 Carl Zeiss Meditec AG

      4. 6.1.4 Essilor International SA

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Nidek Co. Ltd

      7. 6.1.7 Topcon Corporation

      8. 6.1.8 Ziemer Group AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Japan Ophthalmic Device & Drug Industry Segmentation

As per the scope of the report, ophthalmology devices are the equipment that is used for the diagnosis and treatment of various ophthalmic diseases, such as cataracts, glaucoma, and refractive errors. Ophthalmic drugs are used to treat eye infections and some of the above-mentioned diseases. The drugs covered in the report are glaucoma drugs, retinal disorder drugs, dry eye disease drugs, drugs for infections, and other drugs. The Japan Ophthalmic Devices & Drugs Market is Segmented By Product (Devices (Surgical Devices (Intraocular Lenses, Ophthalmic Lasers, and Other Surgical Devices), and Diagnostic Devices), and Drugs (Glaucoma Drugs, Retinal Disorder Drugs, Dry Eye Drugs, Allergic Conjunctivitis and Inflammation Drugs, and Other Drugs), and Disease (Glaucoma, Cataract, Age-Related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Other Diseases). The report offers the value (in USD million) for the above segments.

By Product
Devices
Surgical Devices
Intraocular Lenses
Ophthalmic Lasers
Other Surgical Devices
Diagnostic Devices
Drugs
Glaucoma Drugs
Retinal Disorder Drugs
Dry Eye Drugs
Allergic Conjunctivitis and Inflammation Drugs
Other Drugs
By Disease
Glaucoma
Cataract
Age-Related Macular Degeneration
Inflammatory Diseases
Refractive Disorders
Other Diseases
Need A Different Region Or Segment?
Customize Now

Japan Ophthalmic Device & Drug Market Research FAQs

The Japan Ophthalmic Devices & Drugs Market is projected to register a CAGR of 2% during the forecast period (2024-2029)

Nidek Co. Ltd, Alcon Inc., Bausch Health Companies Inc, Carl Zeiss Meditec AG and Topcon Corporation are the major companies operating in the Japan Ophthalmic Devices & Drugs Market.

The report covers the Japan Ophthalmic Devices & Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Japan Ophthalmic Devices & Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Japan Eye Care Industry Report

Statistics for the 2024 Japan Eye Care market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Japan Eye Care analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Japan Ophthalmic Devices & Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)